Veeva Earnings: Customer Wins and AI Progress Fuel Momentum

Veeva Systems reported fiscal Q2 2027 revenue of $928M (+18% YoY), with GAAP operating income up 40% to $275M. Vault CRM adoption grew, with 12 of the top 20 biopharma companies committed. AI integration is expanding, with early adopters for the Falcon platform. Management raised its full-year revenue outlook to ~$3.685B.

Veeva Systems (VEEV) stock rose 13.8% after its Q2 fiscal 2027 earnings beat estimates, with adjusted EPS of $2.35 on revenue of $928M, up 18% YoY. The company also raised its full-year guidance above analyst expectations.

Veeva Systems (VEEV) shares rose 15% to $282.13 after strong quarterly results and raised fiscal 2027 revenue guidance. GF Value™ estimates VEEV is 3.7% undervalued with a GF Score™ of 90/100. Subscription revenue grew 16% YoY to $766.8M, and the company projects $3.68B-$3.69B in revenue for 2027.

Veeva Systems (VEEV) stock surged 15.2% after reporting Q2 2027 earnings, with revenue of $927.96M (up 17.6% YoY) and EPS of $1.68 (up 37.4% YoY). Net income excluding items was $273.43M (up 36.5% YoY). The company highlighted CRM wins and AI progress, raising FY27 guidance. Investors paid a 45.2x trailing P/E for the profit growth.

Veeva Systems reported $928M in Q2 2027 revenue, up 13% YoY, with non-GAAP operating income of $416M, exceeding guidance. CEO Peter Gassner highlighted record CRM performance and strong momentum for AI product Falcon. The company raised full-year guidance, citing broad-based commercial strength and strategic product transitions in R&D. Vault CRM gained adoption among top biopharma companies, and Falcon saw high early interest. Aspen, a horizontal CRM startup within Veeva, was noted for its simpl

Veeva Systems (VEEV) rose 15% after reporting better-than-expected quarterly earnings and revenue, and raising full-year guidance. Shares gained $37.22 to close at $284.05.